Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Minervax ApS
BioCentury | Nov 15, 2024
Management Tracks
Howard Hechler named CEO of Lumicell
Plus: Veronica Fonck becomes chair of MinervaX, and updates from Grey Wolf, Actimed and Caszyme
BioCentury | Oct 12, 2023
Politics, Policy & Law
Oct. 11 Quick Takes: European Parliament proposes amendments to pharma legislation
Plus: Early stop for Novo’s kidney outcomes study of semaglutide; Agomab raises $100M series B; and updates from MinervaX, FDA, ARPA-H, Tempest, Kanvas-Federation Bio
BioCentury | Jan 6, 2023
Management Tracks
Singhal to lead development at Biogen as company splits R&D
Plus: Baumal named CMO at Apellis, and updates from Pheast, Sofinnova Partners, GE, Lexeo and more
BioCentury | Dec 16, 2022
Finance
Dec. 15 Quick Takes: Enlaza debuts with $61M, covalent targeting biologics platform
Plus: MinervaX taking strep vaccine to Phase II and updates from AbbVie, Prothena, Astria, Guardant and more
BioCentury | Oct 8, 2021
Management Tracks
Doyle joins Aro as CMO
Plus: CytoDyn, HealthCap, MinervaX, Oculis and more
BioCentury | Feb 18, 2021
Finance
With $300M fund, Adjuvant picks its spots among start-ups addressing global public health needs
Gates, GHIF veterans to back start-ups addressing underserved populations
BioCentury | Dec 17, 2020
Finance
Dec. 16 Quick Takes: Neurogene raises $115M while BioAtla sees first-day pop; plus fundings for Atsena, MinervaX, Vivace, Arvinas
Megaround for gene therapy play NeurogeneNeurogene Inc. raised $115 million in a series B round led by EcoR1 Capital, with participation by existing investors Redmile Group, Samsara BioCapital and
BioCentury | Jan 18, 2020
Finance
Novo seeks to REPAIR funding in antibiotics companies
The REPAIR Impact Fund is building a reserve to support portfolio companies through Phase II trials
BioCentury | Jan 18, 2020
Finance
Novo seeks to REPAIR funding in antibiotics companies
The REPAIR Impact Fund is building a reserve to support portfolio companies through Phase II trials
Items per page:
1 - 10 of 17